$6.82
0.74%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US04335A1051
Symbol
ARVN

Arvinas, Inc. Stock price

$6.82
-0.44 6.06% 1M
-1.96 22.32% 6M
-5.04 42.50% YTD
-4.22 38.22% 1Y
-14.10 67.40% 3Y
-74.74 91.64% 5Y
-9.23 57.51% 10Y
-9.23 57.51% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.05 0.74%
ISIN
US04335A1051
Symbol
ARVN
Industry

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$446.6m
Enterprise Value
$-111.6m
Net debt
positive
Cash
$558.4m
Shares outstanding
65.5m
Valuation
P/E
negative
P/S | estimate
1.6 | 1.6
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
0.7 | 0.6
P/B
0.9
Financial Health
Equity Ratio
60.4%
Return on Equity
-18.6%
ROCE
-5.4%
ROIC
-229.4%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$31.7m | 11.5%
SBC as % of FCF
-
SBC Growth 1Y
-46.1%
Share Count Growth 1Y
-7.5%
Shareholder Yield
7.5%
Financials
Revenue | estimate
$275.3m | $282.8m
EBITDA
$-26.2m
EBIT
$-28.9m
Net Income
$-9.5m
Free Cash Flow | ex SBC
$-159.8m | $-191.5m
Growth
Revenue | estimate
-11.9% | 7.7%
EBITDA
73.4%
EBIT
71.6%
Net Income
83.7%
Free Cash Flow
51.5%
Margin
Gross
87.6%
EBITDA
-9.5%
EBIT
-10.5%
Net
-3.5%
Free Cash Flow | ex SBC
-58.1% | -69.6%
More
EPS
$-0.1
FCF per Share
$-2.4
Short interest
10.2%
Employees
246
Rev per Employee
$1.1m

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Arvinas, Inc. forecast:

13x Buy
57%
9x Hold
39%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Arvinas, Inc. forecast:

Buy
57%
Hold
39%
Sell
4%

Arvinas, Inc. Events

Past Events
NOV
3
Q3 2026 Earnings Call
15 days ago
SEP
16
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
4
Q2 2026 Earnings Call
4 months ago
MAY
12
Q1 2026 Earnings Call
6 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago
FEB
24
Q4 2025 Earnings Call
9 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Arvinas, Inc.

Sep '26
+/-
%
275 275
12% 12%
100%
- Direct Costs 9.10 9.10
-
3%
241 241
-
88%
- Selling and Administrative Expenses 77 77
28% 28%
28%
- Research and Development Expense 221 221
28% 28%
80%
-26 -26
73% 73%
-10%
- Depreciation and Amortization 2.70 2.70
21% 21%
1%
EBIT (Operating Income) EBIT -29 -29
72% 72%
-10%
Net Profit -9.50 -9.50
84% 84%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
●
15 days ago
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 – – Demonstrated novel oculomotor and biomarker movement with ARV-102 Phase 1 clinical data in patients with Parki...
Neutral
GlobeNewsWire
●
22 days ago
– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 – NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted prote...
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO Dr. Houston
Employees 246
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today